• Users Online: 736
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Browse Articles Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2020  |  Volume : 11  |  Issue : 1  |  Page : 86

Clinical manifestation and the risk of exposure to SARS-CoV-2 (COVID-19)

1 Young Researchers and Elite Club, Shahrekord Branch, Islamic Azad University; Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 Student Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 Social Determinants of Health Research Center, School of Allied Medical Scinces, Shahrekord University of Medical Sciences, Shahrekord, Iran

Date of Submission23-Mar-2020
Date of Acceptance10-Apr-2020
Date of Web Publication09-Jul-2020

Correspondence Address:
Ali Hasanpour-Dehkordi
Social Determinants of Health Research Center, School of Allied Medical Scinces, Shahrekord University of Medical Sciences, Shahrekord
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijpvm.IJPVM_145_20

Rights and Permissions

How to cite this article:
Aleebrahim-Dehkordi E, Reyhanian A, Hasanpour-Dehkordi A. Clinical manifestation and the risk of exposure to SARS-CoV-2 (COVID-19). Int J Prev Med 2020;11:86

How to cite this URL:
Aleebrahim-Dehkordi E, Reyhanian A, Hasanpour-Dehkordi A. Clinical manifestation and the risk of exposure to SARS-CoV-2 (COVID-19). Int J Prev Med [serial online] 2020 [cited 2022 Jun 25];11:86. Available from: https://www.ijpvmjournal.net/text.asp?2020/11/1/86/289255

The new coronavirus that scientifically has been named SARS-CoV-2 would result in coronavirus disease (COVID-19). It has drawn much attention to itself in the world; consequently, the World Health Organization (WHO) announced in a statement that the outbreak of the virus was a cause of public health emergencies around the world.[1] The outbreak of COVID-19, the novel coronavirus, was first begun in Wuhan, China, with widespread. Due to the increasing prevalence of the disease in more than 120 countries, the WHO has declared a global epidemic on March 21.[2],[3] The virus that causes COVID-19 has been identified as acute respiratory syndrome coronavirus (SARS-CoV-2). In phylogenetic analysis, the virus belongs to the same sex as the Mercury and SARS virus. Pneumonia is the most common manifestation of COVID-19 infection in the early stages characterized by fever, cough, shortness of breath, and bilateral infiltration in chest imaging. Also, in acute cases, it can lead to fatal lung injury and death.[4],[5] The results of a study showed that ACE2 is an important SARS-CoV receptor that keeps safe the lungs from harm or damage. ACE2 is a membrane aminopeptidase that is presented in various human tissues consisting of the vascular endothelial, respiratory tract, small intestine, cardiovascular, and renal systems.[6] According to the latest meta-analysis study on 50466 patients with COVID-19, the death rate has reached 4.3%. However, most people who have died had previous underlying diseases, such as hypertension, diabetes, or cardiovascular disease, which weakened their immune systems. The results of this study showed that fever, cough, muscle pain, or fatigue were the most common clinical symptoms in these patients. In addition, acute respiratory distress syndrome and abnormal chest radiography were seen in 14.8% and 96.6% of the cases with COVID-19, respectively.[7] The studies have shown that people with underlying diseases are at greater risk for complications and deaths from COVID-19. Approximately, 50% of hospitalized patients with suspected new coronavirus have other chronic illnesses and about 40% of hospitalized patients with confirmed new coronavirus infection (SARS-CoV-2) have cardiovascular or cerebrovascular diseases.[8] Since the coronavirus outbreak, some cases have been seen in children and adults with severe symptoms varying across.[9] The primary death cases by COVID-19 occurred in older adults, possibly due to the weak immune system that allows the faster progression of the viral infection.[10],[11] According to the results of another study, among 1099 patients with laboratory-confirmed COVID-19, the patients who had at least one comorbidity disease, such as hypertension, coronary heart disease as well as diabetes were involved the most common cases. In this study, 223 patients had hepatitis B infection; severe cases were more likely to have hepatitis B infection than non-severe cases. Abnormal liver function tests, including elevated aspartate, alanine aminotransferase, total bilirubin and aminotransferase were noted.[12] Although COVID-19 occurs in everyone and is likely to be transmitted person-to-person, some reports suggest that most people with underlying disease or immunodeficiency are at greater risk. However, for all suspected patients and individuals, respiratory precautions of the droplets, along with standard precautions, are essential.

Ethical considerations

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33.  Back to cited text no. 1
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.  Back to cited text no. 2
Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health- the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020;91:264-6.  Back to cited text no. 3
Carlos WG, Dela Cruz CS, Cao B, Pasnick S, Jamil S. Novel Wuhan (2019-nCoV) Coronavirus. Am J Respir Crit Care Med 2020;201:P7-8.  Back to cited text no. 4
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmunity 2020;109:102433.  Back to cited text no. 5
Fortarezza F, Pezzuto F. COVID-19 nephropathy: What could pathologist say? J Nephropathol 2020;9:e32.  Back to cited text no. 6
Sun P, Qie S, Liu Z, Ren J, Xi JJ. Clinical characteristics of 50466 patients with 2019-Ncov infection. J Med Virol 2020 Feb 28;10.1002/jmv.25735. doi: 10.1002/jmv.25735. Online ahead of print.  Back to cited text no. 7
Xiang L, Yue H, Shunye Z, Yueping L, Ling H, Yubin L, Lingli L. Epidemiological Feature and Outcome of 292 Hospitalized Patients with COVID-19 Under Adequate Medical Resource Condition. Available from SSRN: https://ssrn.com/abstract=3550016 or http://dx.doi.org/10.2139/ssrn.3550016. [Last accessed on 2020 Feb 03].  Back to cited text no. 8
Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-Ncov. Viruses 2020;12:135.  Back to cited text no. 9
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol 2020;92:441-7.  Back to cited text no. 10
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199-207.  Back to cited text no. 11
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; Published on February 28, 2020, and last updated on March 6, 2020, at NEJM.org. DOI: 10.1056/NEJMoa2002032.  Back to cited text no. 12


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded65    
    Comments [Add]    

Recommend this journal